Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

InterMune

InterMune?uq=w9if130k
1998 FOUNDED
M&A STATUS
501-600 EMPLOYEES
M&A LATEST DEAL TYPE
6 FINANCING ROUNDS
Description

Developer of therapies in pulmonology and hepatology. The company's products are approved for the treatment of patients with severe, malignant osteopetrosis and chronic granulomatous disease. It has an advanced-stage development pipeline in the pulmonology area and a research and development-stage pipeline in the hepatology area.

Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Primary Industry
Pharmaceuticals
Acquirer
Primary Office
  • 3280 Bayshore Boulevard
  • Brisbane, CA 94005
  • United States

+1 (415) 000-0000

InterMune Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore InterMune‘s full profile, request access.

Request full access to PitchBook

InterMune Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore InterMune‘s full profile, request access.

Request full access to PitchBook

InterMune Executive Team (7)

Name Title Board
Seat
Contact
Info
John Hodgman Chief Financial Officer & Executive Vice President
Daniel Welch Chief Executive Officer
Jung Choi Senior Vice President, Corporate Development

4 Former Executives

You’re viewing 3 of 7 executives. Get the full list »

InterMune Board Members (8)

Name Representing Role Since Contact
Info
00000 0000000 00 Self Board Member 000 0000
0000-0000000 00000000 Self Board Member 000 0000
00000 0000000 Self Board Member 000 0000

5 Former Board Members

You’re viewing 3 of 8 board members. Get the full list »